The PBS Update March 2026: Landmark Ipi–Nivo Listing + Toripalimab and Cabozantinib
The Oncology Podcast
Chapters
0:00
Welcome And Series Purpose
1:52
Why Short-Form PBS Updates
2:52
March Headlines And Context
3:38
First Tumour-Agnostic Listing Details
6:15
Impact On Access And Rare Cancers
7:30
Toripalimab for nasopharyngeal carcinoma
8:23
Replacing Multiple Indications With One Code
9:20
Cabozantinib for neuroendocrine tumours
10:15
Responsible Use And Real-World Data
11:30
Epcoritamab update in DLBCL
12:36
MDTs, Registries, And Monitoring
13:30
Compassionate access schemes
14:39
Will More Agnostic Listings Follow
16:01
Neoadjuvant Exceptions And Clinician Empowerment
The Oncology Podcast
The PBS Update March 2026: Landmark Ipi–Nivo Listing + Toripalimab and Cabozantinib
Mar 10, 2026
Season 1
Episode 1
The Oncology Network presents PBS Update with Professor Craig Underhill and Rachael Babin
Australia’s PBS has introduced it’s first pan-tumour reimbursement listing for the immunotherapy combination nivolumab plus ipilimumab. In this inaugural episode of PBS Update, Professor Craig Underhill and Rachael Babin break down the key oncology changes from the March 2026 PBS update, including new listings for toripalimab and cabozantinib.
Follow PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.
